3rd International AIDS Society Conference on HIV Pathogenesis and Treatment


Rio de Janeiro - July 24 - 27, 2005

HEPATOCELLULAR CARCINOMA IN 40 HIV/HCV-COINFECTED VERSUS 50 HCV-MONOINFECTED PATIENTS. NORTH AMERICAN HCC IN HIV STUDY GROUP

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C17

Bräu N.1, Xiao P.2, Naqvi Z.3, Taylor L.E.4, Sulkowski M.S.5, Sherman M.6, Trikha A.1, Rigsby M.O.7, Martyn C.3, Dieterich D.T.8, Wright T.L.9, Brown S.T.1, Bini E.J.10
1Veterans Affairs Medical Center, Bronx, NY and Mount Sinai School of Medicine, New York, NY, United States of America, 2NYU Downtown Hospital, New York, NY, United States of America, 3Veterans Affairs Medical Center, Bronx, NY, United States of America, 4The Miriam Hospital, Providence, RI, United States of America, 5Johns Hopkins Medical Institute, Baltimore, Maryland, United States of America, 6Toronto General Hospital, Toronto, ON, Canada, 7VA Connecticut Health Care System, West Haven, CT, United States of America, 8Mount Sinai Medical Center, New York, NY, United States of America, 9Veterans Affairs Medical Center, San Francisco, CA, United States of America, 10VA New York Harbor HCS, New York, NY, United States of America

INTRODUCTION: As HIV-infected patients live longer through HAART, they suffer the consequences of coinfection with the hepatitis C virus (HCV). Few data are available on hepatocellular carcinoma (HCC) in HIV-infected persons. One recent Italian-Spanish study showed that survival of HCC is shorter in HIV-positive than in HIV-negative patients.

METHODS: A retrospective chart review in 14 US and Canadian medical centers identified 40 HIV/HCV-coinfected patients with HCC. They were compared to 50 HCV-monoinfected control patients.

RESULTS: See table for details. Only 1 of 90 patients was female. HIV/HCV patients were younger than HCV patients, and they consumed less alcohol. Time from initial HCV infection to HCC was 7.5 years shorter in HIV/HCV compared to HCV patients. HIV/HCV patients had more frequently extrahepatic metastases than HCV patients, but the rate of portal vein thrombosis was the same (7.5% vs. 2.0%). Median survival was similar in both groups (table). Both groups were similar in median AFP levels (1,470 vs. 730 ng/ml) and other laboratory values. There was also no difference in mean Child-Turcotte-Pugh (CTP) scores (7.5 vs. 7.6), Cancer of the Liver Italian Project (CLIP) tumor staging scores (3.0 vs. 2.7), and frequencies of receiving any HCC therapy (58% vs. 40%, p=0.10).

CONCLUSIONS: HIV/HCV-coinfected patients develop HCC at a younger age than HCV-monoinfected patients due to a shorter interval from HCV infection to HCC. In contrast to the European study, we did not find a difference in survival between HIV/HCV and HCV patients.

Acrobat ReaderDownload PDF of this abstract.

050724
Clinical | TuPe1.1C17 | Norbert Bräu
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.